In people, GLP-1 receptor agonists (GLP-1RAs) are commonly used for the treatment of type 2 diabetes mellitus (DM) and obesity; however, non-adherence to injectable medications is common. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.